Shares in Ceres Power shifted sharply higher, rising 7.7% to £374.00, as buyers extended a rebound that began around July 29 after a bruising round of profit-taking knocked the stock from £384 to as low as £307 in three sessions. The bounce matters because it tests whether investors genuinely believe in the long-term business case — or are simply trading a volatile name that has delivered jaw-dropping gains but still generates no profit.
• A Near-1,000% Rally Invited Sellers — and Now Bargain Hunters
Ceres pushed one-year gains close to 1,000% by May , and the stock had been "the darling of the FTSE 250" since June 2025, but things cooled, with shares trading at nearly half their early-June peak by July 1. The late-July dip to £307 gave dip-buyers an entry point roughly 35% below the stock's spring highs. The rebound to £374 signals renewed appetite, but the price remains well below the June placing price of £570 — a reminder of how far the stock has already corrected.
• £103 Million in Fresh Cash Buys Time, Not Earnings
Ceres completed a £103 million fundraising through the issuance of 18 million new shares, equivalent to roughly 9.2% of existing share capital.
Net proceeds of approximately £100 million will accelerate commercial development and support partner expansion. But the company continues to report losses and negative cash flow , and 2025 revenue fell 37% to £32.6 million.
Contracted 2026 revenue stands at roughly £45 million before new business. Shareholders are funding a bridge to a future that has not yet produced positive earnings.
• Licensing Partners Are Moving, but Execution Risk Remains Real
Doosan commenced mass manufacture at a 50MW facility in South Korea in mid-2025, validating the licensing model and generating Ceres' first royalty revenues.
Delta Electronics struck a £43 million licensing deal, with production set for 2026.
Centrica signed a partnership to deploy multi-gigawatt fuel-cell power solutions across the UK and Europe. Yet most licensee markets remain subsidy-driven, making Ceres doubly dependent — on partners who themselves depend on government policy.
• Valuation Demands a Leap of Faith
The most recent analyst price target sits at £930 — more than double today's price — but valuation remains difficult to assess due to the absence of earnings and a dividend, leaving execution and commercial progress as the key factors. At £374, investors are pricing in conviction that royalties will scale. If that thesis stalls, the profit-taking cycle will repeat — fast.